期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms24065270
关键词
ADHD; co-morbidity; epilepsy; neurodevelopment; genetics
Comorbidities are common in children with epilepsy, and ADHD is one of the most prevalent comorbidities. The burden of ADHD in children with epilepsy is high and can negatively impact their clinical outcomes, psychosocial aspects, and quality of life. Stimulants have shown effectiveness and safety in treating comorbid ADHD, but further research is needed to establish their safety in randomized, double-blinded, placebo-controlled trials.
Comorbidities are common in children with epilepsy, with nearly half of the patients having at least one comorbidity. Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder characterized by hyperactivity and inattentiveness level disproportional to the child's developmental stage. The burden of ADHD in children with epilepsy is high and can adversely affect the patients' clinical outcomes, psychosocial aspects, and quality of life. Several hypotheses were proposed to explain the high burden of ADHD in childhood epilepsy; the well-established bidirectional connection and shared genetic/non-genetic factors between epilepsy and comorbid ADHD largely rule out the possibility of a chance in this association. Stimulants are effective in children with comorbid ADHD, and the current body of evidence supports their safety within the approved dose. Nonetheless, safety data should be further studied in randomized, double-blinded, placebo-controlled trials. Comorbid ADHD is still under-recognized in clinical practice. Early identification and management of comorbid ADHD are crucial to optimize the prognosis and reduce the risk of adverse long-term neurodevelopmental outcomes. The identification of the shared genetic background of epilepsy and ADHD can open the gate for tailoring treatment options for these patients through precision medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据